Literature DB >> 32111607

Disparity of microaneurysm count between ultrawide field colour imaging and ultrawide field fluorescein angiography in eyes with diabetic retinopathy.

Mohamed Ashraf1,2, Konstantina Sampani1, Omar AbdelAl1, Alan Fleming3, Jerry Cavallerano1,4, Ahmed Souka2, Samir Mohamed El Baha2, Paolo S Silva1,4, Jennifer Sun1,4, Lloyd Paul Aiello5,4.   

Abstract

AIMS: To compare microaneurysm (MA) counts using ultrawide field colour images (UWF-CI) and ultrawide field fluorescein angiography (UWF-FA).
METHODS: Retrospective study including patients with type 1 or 2 diabetes mellitus receiving UWF-FA and UWF-CI within 2 weeks. MAs were manually counted in individual Early Treatment Diabetic Retinopathy Study (ETDRS) and extended UWF zones. Fields with MAs ≥20 determined diabetic retinopathy (DR) severity (0 fields=mild, 1-3=moderate, ≥4=severe). UWF-FA and UWF-CI agreement was determined and UWF-CI DR severity sensitivity analysis adjusting for UWF-FA MA counts performed.
RESULTS: In 193 patients (288 eyes), 2.4% had no DR, 29.9% mild non-proliferative DR (NPDR), 32.6% moderate (NPDR), 22.9% severe NPDR and 12.2% proliferative DR. UWF-FA MA counts were 3.5-fold higher (p<0.001) than UWF-CI counts overall, 3.2x-fold higher in ETDRS fields (p<0.001) and 5.3-fold higher in extended ETDRS fields (p<0.001) and higher in type 1 versus type 2 diabetes (p<0.001). In eyes with NPDR on UWF-CI (n=246), UWF-FA images had 1.6x-3.5x more fields with ≥20 MAs (p<0.001). Fair agreement existed between imaging modalities (k=0.221-0.416). In ETDRS fields, DR severity agreement increased from k=0.346 to 0.600 when dividing UWF-FA counts by a factor of 3, followed by rapid decline in agreement thereafter. Total UWF area agreement increased from k=0.317 to 0.565 with an adjustment factor of either 4 or 5.
CONCLUSIONS: UWF-FA detects threefold to fivefold more MAs than UWF-CI and identifies 1.6-3.5-fold more fields affecting DR severity. Differences exist at all DR severity levels, thus limiting direct comparison between the modalities. However, correcting UWF-FA MA counts substantially improves DR severity agreement between the modalities. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  diabetic retinopathy; fluorescein angiography; microaneurysm; ultrawide field imaging

Mesh:

Year:  2020        PMID: 32111607     DOI: 10.1136/bjophthalmol-2019-315807

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.

Authors:  Paolo S Silva; Dennis M Marcus; Danni Liu; Lloyd Paul Aiello; Andrew Antoszyk; Michael Elman; Scott Friedman; Adam R Glassman; Joseph M Googe; Lee Merrill Jampol; Daniel F Martin; Michele Melia; Carin M Preston; Charles C Wykoff; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2022-10-01       Impact factor: 8.253

2.  Interaction Between the Distribution of Diabetic Retinopathy Lesions and the Association of Optical Coherence Tomography Angiography Scans With Diabetic Retinopathy Severity.

Authors:  Mohamed Ashraf; Konstantina Sampani; Abdulrahman Rageh; Paolo S Silva; Lloyd Paul Aiello; Jennifer K Sun
Journal:  JAMA Ophthalmol       Date:  2020-12-01       Impact factor: 7.389

3.  Factors Affecting Predominantly Peripheral Lesion Identification and Grading.

Authors:  Mohamed Ashraf; Abdulrahman Rageh; Michael Gilbert; Dorothy Tolls; Alan Fleming; Ahmed Souka; Samir El-Baha; Jerry D Cavallerano; Jennifer K Sun; Lloyd Paul Aiello; Paolo S Silva
Journal:  Transl Vis Sci Technol       Date:  2021-06-01       Impact factor: 3.048

Review 4.  Ultrawide Field Imaging in Diabetic Retinopathy: Exploring the Role of Quantitative Metrics.

Authors:  Mohamed Ashraf; Jerry D Cavallerano; Jennifer K Sun; Paolo S Silva; Lloyd Paul Aiello
Journal:  J Clin Med       Date:  2021-07-27       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.